Amarin Pharma, Inc. et al v. Roxane Laboratories, Inc. et.al,

Filing 110

ORDER granting ECF No. 108 Stipulation to Extend Time for Plaintiffs to File Their Reply claim Construction Brief. Reply brief due by 2/2/2018. Signed by Judge Miranda M. Du on 1/4/2018. (Copies have been distributed pursuant to the NEF - KW)

1
2
3
4
5
6
7
8
9
10
11
12

Nicholas J. Santoro (Nev. Bar No. 532)
Jason D. Smith (Nev. Bar No. 9691)
SANTORO WHITMIRE, LTD.
10100 W. Charleston Blvd., Suite 250
Las Vegas, Nevada 89135
Telephone: [phone]
Facsimile: [phone]
E-mail: [e-mail],
[e-mail]
Christopher N. Sipes (admitted pro hac vice)
Einar Stole (admitted pro hac vice )
Michael N. Kennedy (admitted pro hac vice)
Megan P. Keane (admitted pro hac vice )
COVINGTON & BURLING LLP
One CityCenter, 850 Tenth Street, NW
Washington, DC 20001
Telephone: [phone]
Facsimile: [phone]
E-mail: [e-mail], [e-mail],
[e-mail], [e-mail]

13
14

Attorneys for Plaintiffs Amarin Pharma, Inc. and
Amarin Pharmaceuticals Ireland Limited

15
16

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

17
18
19

AMARIN PHARMA, INC. and AMARIN
PHARMACEUTICALS IRELAND LIMITED,

20
21

Plaintiffs,

24
25
26
27
28

(Consolidated with 2:16-cv-02562-MMD-NJK,
2:16-cv-02658-MMD-NJK, and Case No. 2:17cv-02641-MMD-NJK)

v.

22
23

Case No.: 2:16-cv-02525-MMD-NJK

WEST-WARD PHARMACEUTICALS CORP., et.
al.,
Defendants.

STIPULATION AND ORDER TO
EXTEND TIME FOR PLAINTIFFS TO
FILE THEIR REPLY CLAIM
CONSTRUCTION BRIEF
(First Request)

1

IT IS HEREBY STIPULATED and agreed by and between Plaintiffs Amarin Pharma, Inc. and

2

Amarin Pharmaceuticals Ireland Limited (collectively, “Plaintiffs” or “Amarin”) and Defendants West-

3

Ward Pharmaceuticals Corp., West-Ward Pharmaceuticals International Limited, Dr. Reddy’s

4

Laboratories, Inc., Dr. Reddy’s Laboratories, Ltd., and Teva Pharmaceuticals USA, Inc. (collectively,

5

“Defendants”), by and through their respective undersigned counsel, that the deadline by which Amarin

6

must file their Reply Claim Construction Brief be extended to February 2, 2018. Amarin’s current

7

deadline is January 25, 2018. (ECF No. 60.) This stipulation is therefore filed more than 21 days in

8

advance of the deadline sought to be extended, as required by Local Rule 26-4. This is the parties’ first

9

request to extend the deadline for Amarin’s Reply Claim Construction Brief.

10

At this point, the parties have complied with the previous deadlines in the Discovery Plan and

11

Scheduling Order. (See ECF No. 60 at 1–2; ECF No. 88.) The parties are currently engaged in briefing

12

the claim construction issues in advance of the April 24, 2018 claim construction hearing. (See ECF No.

13

60, ECF No. 103.) Amarin submitted its Opening Claim Construction Brief on November 1, 2017

14

(ECF No. 89) with the supporting Declaration of Dr. Michael Miller, M.D. (ECF No. 89-1). On

15

December 12, 2017, Defendants submitted their Responsive Claim Construction Brief (ECF No. 102)

16

with the supporting Declaration of Ronald H. Wharton, M.D. (ECF No. 102-1).

17

The parties have long contemplated that the claim construction declarants would be deposed

18

during the claim construction stages of this case. For example, in the Proposed Discovery Plan

19

Scheduling Order, Amarin explained that “[t]hese deposition are necessary to ensure that the parties can

20

adequately respond to any testimony that is submitted in support of the parties’ claim construction

21

positions.” (ECF No. 55 at 7.) However, Defendants’ claim construction declarant, Dr. Wharton, is not

22

available for his deposition until January 24, 2018—the day before the current deadline for Amarin’s

23

Reply Claim Construction Brief. Accordingly, good cause exists for the requested extension. Without

24

the requested extension, Amarin will be deprived of any meaningful opportunity to address the

25

testimony that Dr. Wharton will give at his January 24, 2018 deposition before filing its Reply Brief due

26

the next day. The requested extension provides adequate time to obtain the final transcript from the

27

deposition, review the transcript, and revise the brief in accordance with the deposition testimony. The

28

-2-

1

prejudice to Amarin from the current schedule is particularly acute because Wharton opines that many of

2

Amarin’s patent claims are invalid. (See Wharton Decl. ¶¶ 64–73, ECF No. 102-1.) Thus, without the

3

extension, Amarin would be essentially precluded from addressing Dr. Wharton’s claim construction

4

opinions in its Reply Brief, but also unable to fully respond to Dr. Wharton’s opinions that many of

5

Amarin’s patent claims should be found invalid at this very early stage of the case. See Phillips v. AWH

6

Corp., 415 F.3d 1303, 1318 (Fed. Cir. 2005) (“[E]xtrinsic evidence consisting of expert reports and

7

testimony . . . can suffer from bias . . . . The effect of that bias can be exacerbated . . . if the expert's

8

opinion is offered in a form that is not subject to cross-examination.”).
The parties further stipulate and agree that the requested extension will not be prejudicial to any

9
10

party. The additional eight days will not impede on any of the parties’ abilities to prepare for the April

11

24, 2018 claim construction hearing. Indeed, even with the requested extension to February 2, 2018, the

12

parties and the Court will be in possession of all claim construction briefing for well over two months

13

before the hearing. In addition, Amarin agrees to make its claim construction declarant, Dr. Miller,

14

available for deposition between February 9, 2018 and March 31, 2018, as requested by Defendants.

15

Moreover, the requested extension will not affect any other currently scheduled case deadline. (ECF No.

16

60.)

17

Finally, there have been no previous extensions of time with respect to the deadline for Amarin’s

18

Reply Claim Construction Brief. Accordingly, the parties stipulate that Amarin shall have up to and

19

including February 2, 2018, to file its Reply Claim Construction Brief.

20

DATED: January 3, 2018

Respectfully submitted,

21

/s/ Jason D. Smith
Nicholas J. Santoro (Nev. Bar No. 532)
Jason D. Smith (Nev. Bar No. 9691)
SANTORO WHITMIRE, LTD.
10100 W. Charleston Blvd., Suite 250
Las Vegas, NV 89135
Tel: [phone] / Fax: [phone]
E-mail: [e-mail],
[e-mail]

/s/ Alan B. Clement
Wayne A. Shaffer (Nev. Bar No. 1519)
LAXALT & NOMURA, LTD.
9600 Gateway Drive
Reno, NV 89521
Tel: [phone] / Fax: [phone]
E-mail: [e-mail]

22
23
24
25
26
27
28

Christopher N. Sipes
Einar Stole

Alan B. Clement
LOCKE LORD LLP
Brookfield Place
200 Vesey Street, 20th Floor
-3-

1
2
3
4
5

Michael N. Kennedy
Megan P. Keane
COVINGTON & BURLING LLP
One CityCenter, 850 Tenth Street, NW
Washington, DC 20001
Tel: [phone] / Fax: [phone]
E-mail: [e-mail], [e-mail],
[e-mail], [e-mail]
Attorneys for Plaintiffs Amarin Pharma, Inc. and
Amarin Pharmaceuticals Ireland Limited

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

/s/ Constance S. Huttner
Michael D. Rounds (Nev. Bar No. 4764)
Ryan J. Cudnik (Nev. Bar No. 12948)
BROWNSTEIN HYATT FARBER
SCHRECK, LLP
5371 Kietzke Lane
Reno, NV 89511
Tel: [phone] / Fax: [phone]
E-mail: [e-mail],
[e-mail]
Constance S. Huttner
Caroline Sun
BUDD LARNER, P.C.
150 John F. Kennedy Parkway
Short Hills, NJ 07078
Tel: [phone] / Fax: [phone]
E-mail: [e-mail],
[e-mail]
Attorneys for Defendants Dr. Reddy’s Laboratories,
Inc. and Dr. Reddy’s Laboratories, Ltd.

New York, NY 10281
Tel: [phone] / Fax: [phone]
E-mail: [e-mail]
Myoka Kim Goodin
Nina Vachhani
Jennifer Coronel
LOCKE LORD LLP
111 S. Wacker Drive
Chicago, IL 60606
Tel: [phone] / Fax: [phone]
Email: [e-mail],
[e-mail],
[e-mail]
Attorneys for Defendants West-Ward
Pharmaceuticals Corp. and West-Ward Pharmaceuticals
International Limited
/s/ J.C. Rosendaal
John P. Desmond (Nev. Bar No. 5618)
Brian R. Irvine (Nev. Bar No. 7758)
DICKINSON WRIGHT PLLC
100 West Liberty St., Suite 940
Reno, NV 89501
Tel: [phone] / Fax: [phone]
E-mail: [e-mail],
[e-mail]
J.C. Rozendaal
Michael E. Joffre
Chandrika Vira
STERNE, KESSLER, GOLDSTEIN & FOX
1100 New York Avenue N.W.
Washington, DC 20005-3934
Tel: [phone] / Fax: [phone]
E-mail: [e-mail], [e-mail],
[e-mail]
Attorneys for Defendant Teva Pharmaceuticals USA, Inc.

Amarin shall have up to and including February 2, 2018, to file its Reply Claim Construction Brief.
IT IS SO ORDERED.

25

______________________________________
UNITED STATES DISTRICT JUDGE

26

January 4, 2018
DATED:______________________________

27
28

-4-

1

CERTIFICATE OF SERVICE

2

I hereby certify that on January 3, 2018, I electronically transmitted a true and correct copy

3

of the foregoing STIPULATION AND ORDER TO EXTEND TIME FOR PLAINTIFFS

4

TO FILE THEIR REPLY CLAIM CONSTRUCTION BRIEF (First Request) to the

5

following counsel of record in this matter:
Laxalt & Nomura, Ltd.
Wayne A. Shaffer
Email: [e-mail]
Locke Lord LLP
Alan B. Clement
Email: [e-mail]
Myoka Kim Goodin
Email: [e-mail]
Nina Vachhani
Email: [e-mail]
Jennifer Coronel
Email: [e-mail]
Attorneys for Defendants West-Ward Pharmaceuticals Corp. and West-Ward Pharmaceuticals Limited
International

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Brownstein Hyatt Farber Schreck, LLP
Michael D. Rounds
Email: [e-mail]
Ryan James Cudnik
Email: [e-mail]
Budd Larner, P.C.
Constance S. Huttner
Email: [e-mail]
Caroline Sun
Email: [e-mail]
Beth Finkelstein
Email: [e-mail]
Attorneys for Defendants Dr. Reddy’s Laboratories, Inc. and Dr. Reddy’s Laboratories, Ltd.
Dickinson Wright PLLC
John P. Desmond
Email: [e-mail]
Brian R. Irvine
Email: [e-mail]
Sterne, Kessler, Goldstein & Fox P.L.L.C.
J.C. Rozendaal
Email: [e-mail]
Michael E. Joffre
Email: [e-mail]
Chandrika Vira
Email: [e-mail]
Attorneys for Defendant Teva Pharmaceuticals USA, Inc.

21
22

/s/ Rachel Jenkins
An employee of Santoro Whitmire

23
24
25
26
27
28

-5-